Key facts
CAS number:50-76-0,
Purity:>98%,
Form:SolidSee storage information,
Source:Streptomyces sp.,
Molecular weight:1255.4 Da,
Molecular formula:C62H86N12O16,
PubChem:2019,
Nature:Native,
Solubility:Soluble in 20 mg/mL (in DMSO),
Biochemical name:actinomycin D,
Biological description:Nucleic acid and protein synthesis inhibitor. Intercalates DNA, stabilizes topoisomerases I and II and inhibits transcription. Antibacterial and antitumor agent. Active in vivo and in vitro.,
Canonical smiles:CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C,
InChi:InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79),
InChiKey:RJURFGZVJUQBHK-UHFFFAOYSA-N,
IUPAC Name:2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
Product details:
This product is hygroscopic. Unused dilute solutions of Actinomycin D are extremely sensitive to light and tend to adsorb to plastic and glass and should be discarded. However, frozen aliquots of concentrated stock solution are stable for at least a month.
Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-It is important to note that this product is reported to be light sensitive, Store in the dark
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Interferon beta also known as IFN-beta or beta interferon is a type I interferon with a mass of approximately 20 kDa. It originates primarily from fibroblasts and plays an essential role in the immune response. This protein targets and binds to specific cell surface receptors initiating various antiviral states within cells. This action assists in slowing down viral replication and spread. IFN-beta's expression increases in response to viral infections making it an important component in the body's first line of defense against pathogens.
Biological function summary
Interferon beta functions as an important mediator of immune functions regulating the activity of natural killer cells and macrophages. It also boosts antigen presentation to T cells. Interferon beta belongs to the larger family of interferons which includes IFN-alpha and IFN-gamma each having distinct effects but working together to mount an effective immune response. Though it does not form part of a complex it plays a critical standalone role in immune signaling pathways.
Pathways
Interferon beta associates strongly with the JAK-STAT signaling pathway. Upon activation it interacts with receptors to phosphorylate STAT proteins mainly STAT1 and STAT2 which then dimerize and translocate to the nucleus to trigger gene expression. Another important pathway is the antiviral response where interferon beta modulates the expression of hundreds of interferon-stimulated genes. These pathways intricately involve other proteins like IFN-alpha and IFN-gamma which work synergistically to establish an effective antiviral environment.
Interferon beta shows significant implications in multiple sclerosis and hepatitis C infection. It is widely used as a therapeutic agent in managing multiple sclerosis by modulating the immune response to reduce inflammation and slow disease progression. Similarly its role in antiviral defense makes it relevant to hepatitis C infection management. In these contexts IFN-alpha and IFN-gamma are also important as they share similar antiviral and immunomodulatory functions that can complement IFN-beta's actions enhancing the treatment's efficacy.
